Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Taylor, Peter C. http://orcid.org/0000-0001-7766-6167
Elboudwarej, Emon
Hertz, Angie
Shao, Xiaorong
Malkov, Vladislav A.
Matsushima, Hironori
Emoto, Kahaku
Downie, Bryan
Takeuchi, Tsutomu
Clinical trials referenced in this document:
Documents that mention this clinical trial
POS0518 EFFECT OF FILGOTINIB (FIL) ON BODY WEIGHT (BW) AND BODY MASS INDEX (BMI) AND EFFECT OF BASELINE BMI ON THE EFFICACY AND SAFETY OF FIL IN RHEUMATOID ARTHRITIS (RA)
https://doi.org/10.1136/annrheumdis-2022-eular.1088
POS0704 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.5051
OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.3967
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
https://doi.org/10.1136/annrheumdis-2020-eular.276
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
https://doi.org/10.1007/s40744-022-00503-3
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0679 CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1641
AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1316
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
https://doi.org/10.1007/s40744-023-00583-9
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
https://doi.org/10.1007/s40744-023-00619-0
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
FRI0128 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.2882
FRI0136 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)
https://doi.org/10.1136/annrheumdis-2020-eular.4704
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES
https://doi.org/10.1136/annrheumdis-2021-eular.850
POS0526 SEXUAL FUNCTION IN MALE AND FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF THE FINCH STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.1774
THU0215 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)
https://doi.org/10.1136/annrheumdis-2020-eular.2996
Impact of filgotinib on pain control in the phase 3 FINCH studies
https://doi.org/10.1136/rmdopen-2023-003839
POS0664 RADIOGRAPHIC CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ESTIMATED BASELINE YEARLY PROGRESSION ≥5 OR <5: POST HOC ANALYSIS OF TWO PHASE 3 TRIALS OF FILGOTINIB
https://doi.org/10.1136/annrheumdis-2022-eular.198
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3572
AB0689 SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.2864
POS0536 FILGOTINIB DEMONSTRATES CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS INDEPENDENT OF SMOKING STATUS: A POST-HOC SUBGROUP ANALYSIS OF THREE PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.2128
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.2236
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0843 DISTINCT TREATMENT RESPONSES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING FILGOTINIB 200 MG OVER 12 MONTHS: A POST HOC ANALYSIS OF FINCH 1
https://doi.org/10.1136/annrheumdis-2023-eular.1318
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
https://doi.org/10.1136/annrheumdis-2020-219214
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 21 March 2023
Accepted: 28 June 2023
First Online: 25 July 2023
Change Date: 20 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40744-023-00622-5